Suchergebnisse - "Subklewe, Marion"

PubPharm (85)

1

First-in-human study of JNJ-67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome

enthalten in: Clinical and translational science | 2024

von Narayan, R. | Piérola, A. | Donnellan, W. | +17

2

Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute myeloid leukemia : a preclinical assessment

enthalten in: Leukemia | 2024

von Hänel, G. | Schönle, A. | Neumann, A. | +15

3

The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL

enthalten in: American journal of hematology | 2023

von Rejeski, K. | Wang, Y. | Albanyan, O. | +17

4

Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R/R DLBCL

enthalten in: Blood advances | 2023

von Blumenberg, V. | Busch, G. | Baumann, S. | +24

5

Mechanisms and strategies for safe chimeric antigen receptor T-cell activity control

enthalten in: International journal of cancer | 2023

von Stock, S. | Klüver, A. | Fertig, L. | +4

6

Cooperative CAR targeting to selectively eliminate AML and minimize escape

enthalten in: Cancer cell | 2023

von Haubner, S. | Mansilla-Soto, J. | Nataraj, S. | +11

CommentIn: Cancer Cell. 2023 Nov 13;41(11):1841-1843. - PMID 37832553

7

The race is on : bispecifics vs CAR T cells in B-cell lymphoma

enthalten in: Blood advances | 2023

von Gurumurthi, A. | Westin, J. | Subklewe, M.

8

Prognostic value of pre-infusion tumor growth rate for patients with lymphoma receiving chimeric antigen receptor T-cell therapy

enthalten in: Cytotherapy | 2023

von Winkelmann, M. | Blumenberg, V. | Rejeski, K. | +11

9

Immune effector cell-associated hematotoxicity : EHA/EBMT consensus grading and best practice recommendations

enthalten in: Blood | 2023

von Rejeski, K. | Subklewe, M. | Aljurf, M. | +34

CommentIn: Blood. 2023 Sep 7;142(10):859-861. - PMID 37676695

10

Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3

enthalten in: Journal for immunotherapy of cancer | 2023

von Shah, B. | Cassaday, R. | Park, J. | +26

1
2
3
4
5
6
7
8
9
Nächster »
[9]